Logo image of PATH

UIPATH INC - CLASS A (PATH) Stock Fundamental Analysis

NYSE:PATH - New York Stock Exchange, Inc. - US90364P1057 - Common Stock - Currency: USD

11.97  +0.09 (+0.76%)

After market: 11.9999 +0.03 (+0.25%)

Fundamental Rating

5

Overall PATH gets a fundamental rating of 5 out of 10. We evaluated PATH against 281 industry peers in the Software industry. PATH has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, PATH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year PATH was profitable.
PATH had a positive operating cash flow in the past year.
PATH had negative earnings in each of the past 5 years.
In multiple years PATH reported negative operating cash flow during the last 5 years.
PATH Yearly Net Income VS EBIT VS OCF VS FCFPATH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

PATH's Return On Assets of -2.57% is in line compared to the rest of the industry. PATH outperforms 58.01% of its industry peers.
With a Return On Equity value of -3.99%, PATH perfoms like the industry average, outperforming 58.72% of the companies in the same industry.
Industry RankSector Rank
ROA -2.57%
ROE -3.99%
ROIC N/A
ROA(3y)-5.87%
ROA(5y)-9.74%
ROE(3y)-8.52%
ROE(5y)-15%
ROIC(3y)N/A
ROIC(5y)N/A
PATH Yearly ROA, ROE, ROICPATH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

PATH has a better Gross Margin (82.93%) than 90.39% of its industry peers.
PATH's Gross Margin has been stable in the last couple of years.
PATH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.08%
PATH Yearly Profit, Operating, Gross MarginsPATH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

8

2. Health

2.1 Basic Checks

PATH does not have a ROIC to compare to the WACC, probably because it is not profitable.
PATH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, PATH has more shares outstanding
PATH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PATH Yearly Shares OutstandingPATH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
PATH Yearly Total Debt VS Total AssetsPATH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

An Altman-Z score of 3.87 indicates that PATH is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.87, PATH is doing good in the industry, outperforming 65.84% of the companies in the same industry.
PATH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.87
ROIC/WACCN/A
WACC10.59%
PATH Yearly LT Debt VS Equity VS FCFPATH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B

2.3 Liquidity

PATH has a Current Ratio of 2.93. This indicates that PATH is financially healthy and has no problem in meeting its short term obligations.
PATH has a Current ratio of 2.93. This is in the better half of the industry: PATH outperforms 72.60% of its industry peers.
PATH has a Quick Ratio of 2.93. This indicates that PATH is financially healthy and has no problem in meeting its short term obligations.
PATH's Quick ratio of 2.93 is fine compared to the rest of the industry. PATH outperforms 73.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.93
PATH Yearly Current Assets VS Current LiabilitesPATH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.00% over the past year.
The Earnings Per Share has been growing by 88.99% on average over the past years. This is a very strong growth
PATH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.30%.
Measured over the past years, PATH shows a very strong growth in Revenue. The Revenue has been growing by 33.58% on average per year.
EPS 1Y (TTM)0%
EPS 3Y88.99%
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y17.01%
Revenue growth 5Y33.58%
Sales Q2Q%4.54%

3.2 Future

The Earnings Per Share is expected to grow by 1.84% on average over the next years.
The Revenue is expected to grow by 11.61% on average over the next years. This is quite good.
EPS Next Y1.84%
EPS Next 2Y5.72%
EPS Next 3Y4.45%
EPS Next 5Y1.84%
Revenue Next Year6.64%
Revenue Next 2Y7.81%
Revenue Next 3Y8.27%
Revenue Next 5Y11.61%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PATH Yearly Revenue VS EstimatesPATH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B 2B 2.5B
PATH Yearly EPS VS EstimatesPATH Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0.2 0.4 0.6

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 22.17, PATH is valued on the expensive side.
Based on the Price/Earnings ratio, PATH is valued a bit cheaper than 73.67% of the companies in the same industry.
When comparing the Price/Earnings ratio of PATH to the average of the S&P500 Index (28.22), we can say PATH is valued slightly cheaper.
Based on the Price/Forward Earnings ratio of 21.77, the valuation of PATH can be described as rather expensive.
75.44% of the companies in the same industry are more expensive than PATH, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 20.86. PATH is around the same levels.
Industry RankSector Rank
PE 22.17
Fwd PE 21.77
PATH Price Earnings VS Forward Price EarningsPATH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, PATH is valued a bit cheaper than the industry average as 78.65% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 21.6
EV/EBITDA N/A
PATH Per share dataPATH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PATH does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)12.05
PEG (5Y)N/A
EPS Next 2Y5.72%
EPS Next 3Y4.45%

0

5. Dividend

5.1 Amount

No dividends for PATH!.
Industry RankSector Rank
Dividend Yield N/A

UIPATH INC - CLASS A

NYSE:PATH (5/2/2025, 8:16:28 PM)

After market: 11.9999 +0.03 (+0.25%)

11.97

+0.09 (+0.76%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)03-12 2025-03-12/amc
Earnings (Next)05-28 2025-05-28/amc
Inst Owners66.97%
Inst Owner Change-1.46%
Ins Owners7.05%
Ins Owner Change0.37%
Market Cap6.60B
Analysts65.81
Price Target12.39 (3.51%)
Short Float %8.59%
Short Ratio2.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.25%
Min EPS beat(2)27.1%
Max EPS beat(2)47.41%
EPS beat(4)4
Avg EPS beat(4)26.15%
Min EPS beat(4)10.35%
Max EPS beat(4)47.41%
EPS beat(8)8
Avg EPS beat(8)92.57%
EPS beat(12)12
Avg EPS beat(12)105.9%
EPS beat(16)16
Avg EPS beat(16)107.11%
Revenue beat(2)1
Avg Revenue beat(2)-1.18%
Min Revenue beat(2)-2.36%
Max Revenue beat(2)0%
Revenue beat(4)2
Avg Revenue beat(4)-0.4%
Min Revenue beat(4)-2.36%
Max Revenue beat(4)2.1%
Revenue beat(8)5
Avg Revenue beat(8)0.96%
Revenue beat(12)9
Avg Revenue beat(12)2.46%
Revenue beat(16)13
Avg Revenue beat(16)2.84%
PT rev (1m)-1.18%
PT rev (3m)-22.77%
EPS NQ rev (1m)-0.5%
EPS NQ rev (3m)4.58%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)4.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.84%
Revenue NY rev (1m)-3.71%
Revenue NY rev (3m)-3.77%
Valuation
Industry RankSector Rank
PE 22.17
Fwd PE 21.77
P/S 4.62
P/FCF 21.6
P/OCF 20.59
P/B 3.58
P/tB 3.77
EV/EBITDA N/A
EPS(TTM)0.54
EY4.51%
EPS(NY)0.55
Fwd EY4.59%
FCF(TTM)0.55
FCFY4.63%
OCF(TTM)0.58
OCFY4.86%
SpS2.59
BVpS3.35
TBVpS3.17
PEG (NY)12.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.57%
ROE -3.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.93%
FCFM 21.38%
ROA(3y)-5.87%
ROA(5y)-9.74%
ROE(3y)-8.52%
ROE(5y)-15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.76%
GM growth 5Y0.08%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 86.6%
Cap/Sales 1.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.93
Altman-Z 3.87
F-Score6
WACC10.59%
ROIC/WACCN/A
Cap/Depr(3y)82.11%
Cap/Depr(5y)72.19%
Cap/Sales(3y)1.29%
Cap/Sales(5y)1.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y88.99%
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y1.84%
EPS Next 2Y5.72%
EPS Next 3Y4.45%
EPS Next 5Y1.84%
Revenue 1Y (TTM)9.3%
Revenue growth 3Y17.01%
Revenue growth 5Y33.58%
Sales Q2Q%4.54%
Revenue Next Year6.64%
Revenue Next 2Y7.81%
Revenue Next 3Y8.27%
Revenue Next 5Y11.61%
EBIT growth 1Y14.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.25%
EBIT Next 3Y22.19%
EBIT Next 5Y22.63%
FCF growth 1Y4.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.18%
OCF growth 3YN/A
OCF growth 5YN/A